Acetoxyvalerenic Acid

Acetoxyvalerenic Acid at a Glance

Acetoxyvalerenic acid is the acetylated sibling of valerenic acid — one of the three “valerenic acids” that define valerian root (Valeriana officinalis) and the basis of its pharmacopoeial assay. Structurally it is valerenic acid carrying an extra acetate group; chemically it is unremarkable. Pharmacologically it is one of the more interesting molecules in the herbal materia medica, for a reason that runs the wrong way.

It occupies the same GABA-A binding site as valerenic acid, but it does not potentiate the receptor ^{2,3Reference 2Felgentreff F et al. · 2012Valerian extract characterized by high valerenic acid and low acetoxy valerenic acid contents demonstrates anxiolytic activityView study →Reference 3Khom S et al. · 2007Valerenic acid potentiates and inhibits GABA(A) receptors: molecular mechanism and subunit specificityView study →}. And when it is added back to a valerian extract at ratios typical of commercial products, the extract’s anxiolytic effect in mice disappears ^{1,2Reference 1Becker A et al. · 2014The anxiolytic effects of a Valerian extract is based on valerenic acidView study →Reference 2Felgentreff F et al. · 2012Valerian extract characterized by high valerenic acid and low acetoxy valerenic acid contents demonstrates anxiolytic activityView study →}. In effect, valerian carries an endogenous brake on its own most active constituent.

The practical consequence is where this molecule earns its page. The European Pharmacopoeia monograph for valerian root expresses the sum of valerenic acid and acetoxyvalerenic acid as “valerenic acid” ^{1Reference 1Becker A et al. · 2014The anxiolytic effects of a Valerian extract is based on valerenic acidView study →}. A product can therefore meet its stated “0.8% valerenic acids” and still be pharmacologically self-cancelling, because most of that total may be the acetylated form. Since the ratio between the two acids varies with cultivar, ploidy, harvest month and extraction solvent, this is one of the better mechanistic explanations available for why valerian’s clinical trial record is so stubbornly inconsistent ^{15Reference 15Shinjyo N et al. · 2020Meta-analysisValerian root in treating sleep problems and associated disorders — a systematic review and meta-analysisView study →}.

The isolated literature on this compound is small, and most of it is analytical rather than pharmacological. That is fairly stated up front: this is a short page about a molecule whose importance is structural rather than therapeutic.

The Antagonist Inside the Herb

The core finding comes from two studies by the same German group, both using the elevated plus maze (EPM) in mice with orally dosed valerian extract.

Study one — two extracts, same total acids, different ratios. Felgentreff and colleagues compared two valerian extracts standardised to identical total amounts of valerenic acids but differing in the ratio between valerenic acid (VA) and acetoxyvalerenic acid (AVA): 12:1 versus 1:1.5. The 12:1 extract produced a significant anxiolytic effect at 0.5 mg/kg. The 1:1.5 extract required four times that dose (2.0 mg/kg) to do the same ^{2Reference 2Felgentreff F et al. · 2012Valerian extract characterized by high valerenic acid and low acetoxy valerenic acid contents demonstrates anxiolytic activityView study →}. Their stated conclusion was blunt: standardising to the total amount of valerenic acids “is misleading.”

Study two — add the antagonist back. Becker and colleagues then took the active 12:1 extract, held the total acid dose constant at 0.5 mg/kg, and spiked in pure acetoxyvalerenic acid to shift the ratio to 1:0.5, 1:1 and 1:1.5 — the ratios they note are most commonly reported for standard commercial valerian preparations ^{1,8Reference 1Becker A et al. · 2014The anxiolytic effects of a Valerian extract is based on valerenic acidView study →Reference 8Navarrete A et al. · 2006Chemical fingerprinting of Valeriana species: simultaneous determination of valerenic acids, flavonoids, and phenylpropanoids using liquid chromatography with ultraviolet detectionView study →}. The 12:1 extract again prolonged time on the open arms (20.2% vs 15.2% for saline, p = 0.035). Every spiked combination lost that effect: two fell back to the saline range, and the 1:1 combination was significantly anxiogenic (p = 0.008). Locomotor measures (total arm changes, open-arm entries) did not differ between groups, so this was not a movement artefact, and body core temperature was unchanged ^{1Reference 1Becker A et al. · 2014The anxiolytic effects of a Valerian extract is based on valerenic acidView study →}.

What was shown where — the honest breakdown. This matters, because it is easy to overstate:

• The antagonism of the anxiolytic effect is an in-vivo finding, demonstrated behaviourally in mice in both studies ^{1,2Reference 1Becker A et al. · 2014The anxiolytic effects of a Valerian extract is based on valerenic acidView study →Reference 2Felgentreff F et al. · 2012Valerian extract characterized by high valerenic acid and low acetoxy valerenic acid contents demonstrates anxiolytic activityView study →}.
• The “same binding site, no potentiation” claim is in-vitro, and it is cited rather than demonstrated by those two papers — it rests on the electrophysiology of Khom and Benke, where acetoxyvalerenic acid fails to enhance GABA-evoked chloride current and only inhibits it at high concentration (≥100 µM), consistent with open-channel block ^{3,4Reference 3Khom S et al. · 2007Valerenic acid potentiates and inhibits GABA(A) receptors: molecular mechanism and subunit specificityView study →Reference 4Benke D et al. · 2009AnimalGABA-A receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extractsView study →}.
• Becker’s own radioligand work did not show competition: at the orthosteric GABA site, the whole extracts displaced ³H-GABA (EC50 5.6 and 10.0 µM) but acetoxyvalerenic acid did not, and neither extract bound the benzodiazepine site at all ^{1Reference 1Becker A et al. · 2014The anxiolytic effects of a Valerian extract is based on valerenic acidView study →}. The authors say so explicitly — the EPM interaction “can not be explained based on the binding data presented here.” The site in question is the allosteric β+/α− valerenic-acid pocket, not the GABA site their assay probed.

So: behavioural antagonism, in vivo, replicated once; the molecular mechanism for it is inferred, not directly demonstrated. That is a real finding with a genuinely unfinished mechanistic account, and it should be read that way.

Two further caveats. Both studies come from one research group, and both were industry-supported (Becker 2014 was funded by a German valerian producer, with no competing interests declared) ^{1Reference 1Becker A et al. · 2014The anxiolytic effects of a Valerian extract is based on valerenic acidView study →}. And the dose–response is not linear — the 1:1 mixture was worse than 1:1.5 — which the authors attribute to acetoxyvalerenic acid’s channel-blocking behaviour interacting with the concentration of its competitor ^{1,3Reference 1Becker A et al. · 2014The anxiolytic effects of a Valerian extract is based on valerenic acidView study →Reference 3Khom S et al. · 2007Valerenic acid potentiates and inhibits GABA(A) receptors: molecular mechanism and subunit specificityView study →}. Independent replication is the obvious missing piece.

Why “Total Valerenic Acids” Standardisation Is Misleading

This is the reason the finding has teeth beyond the mouse room.

Valerian root is assayed for sesquiterpenic acids, and the European Pharmacopoeia requires not less than 0.17% in the dried root ^{6Reference 6Raj K et al. · 2023Chemical diversity of wild-growing and cultivated common valerian (Valeriana officinalis L. s.l.) originating from PolandView study →}. But that figure is a total, dominated by valerenic acid and acetoxyvalerenic acid together, and the monograph expresses the sum as valerenic acid ^{1Reference 1Becker A et al. · 2014The anxiolytic effects of a Valerian extract is based on valerenic acidView study →}. Two batches with identical label claims can therefore have opposite pharmacology.

How lopsided can it get? In a 2023 survey of Polish valerian, the cultivated tetraploid ‘Lubelski’ forms — the commercial workhorse — averaged 0.149% valerenic acid and 0.171% acetoxyvalerenic acid, meaning the acetylated form was the larger half of the assay figure ^{6Reference 6Raj K et al. · 2023Chemical diversity of wild-growing and cultivated common valerian (Valeriana officinalis L. s.l.) originating from PolandView study →}. Wild diploid populations ran at 0.011% and 0.002% respectively: far weaker overall, but with a far more favourable ratio. Nothing in a “total valerenic acids” number distinguishes these.

Layered on top are the ordinary sources of botanical variance, each of which moves the two acids independently:

• Cultivar and ploidy — octoploid cytotypes are the most productive for sesquiterpenic acids overall ^{7Reference 7Nikzad-Langerodi R et al. · 2018Quality control of Valerianae Radix by attenuated total reflection Fourier transform infrared (ATR-FTIR) spectroscopyView study →}; ratios differ by form, and one genotype has been described as a hydroxyvalerenic acid chemotype ^{13Reference 13Nell M et al. · 2010Root colonization by symbiotic arbuscular mycorrhizal fungi increases sesquiterpenic acid concentrations in Valeriana officinalis LView study →}.
• Harvest timing — valerenic acid and derivatives peak in February–March ^{12Reference 12Bos R et al. · 1998Seasonal variation of the essential oil, valerenic acid and derivatives, and valepotriates in Valeriana officinalis roots and rhizomes, and the selection of plants suitable for phytomedicinesView study →}.
• Growing conditions — arbuscular mycorrhizal inoculation raised sesquiterpenic acid concentrations in valerian roots (though at a cost to biomass) ^{13Reference 13Nell M et al. · 2010Root colonization by symbiotic arbuscular mycorrhizal fungi increases sesquiterpenic acid concentrations in Valeriana officinalis LView study →}.
• Extraction solvent and temperature — apolar extracts carry the sesquiterpenic acids and modulate GABA-A; polar extracts do not ^{5Reference 5Trauner G et al. · 2008Modulation of GABAA receptors by valerian extracts is related to the content of valerenic acidView study →}. Higher extraction temperatures speed the process but degrade the acids ^{17Reference 17Boyadzhiev L et al. · 2004Extraction of valerenic acids from valerian (Valeriana officinalis L.) rhizomesView study →}.
• Storage — acetoxyvalerenic acid is the labile one: incubated with rat hepatocytes, it fell 9-fold while hydroxyvalerenic acid rose 9-fold, by simple O-deacetylation ^{10Reference 10Simmen U et al. · 2005Preserved pharmacological activity of hepatocytes-treated extracts of valerian and StView study →}; hydroxyvalerenic acid also accumulates as a degradation product during accelerated storage testing ^{18Reference 18Goppel M · 2004Stability control of valerian ground material and extracts: a new HPLC-method for the routine quantification of valerenic acids and lignansView study →}.
• The finished product — a survey of 31 Australian valerian preparations found total valerenic acids from <0.01 to 6.32 mg/g, with standardised products averaging four times the non-standardised ones ^{16Reference 16Shohet D et al. · 2001Valepotriates and valerenic acids in commercial preparations of valerian available in AustraliaView study →}; a Health Canada analysis of 14 commercial products likewise found wide variation, often at odds with label claims ^{19Reference 19Lefebvre T et al. · 2004In vitroIn vitro activity of commercial valerian root extracts against human cytochrome P450 3A4View study →}.

What this implies for choosing a product. Prefer a preparation that declares valerenic acid separately from acetoxyvalerenic acid — which is exactly what Becker’s group argued the monograph should require ^{1Reference 1Becker A et al. · 2014The anxiolytic effects of a Valerian extract is based on valerenic acidView study →}. If only a combined “valerenic acids” figure is available, treat it as an upper bound on the active fraction rather than a measure of it. Alcoholic or otherwise apolar extracts carry the sesquiterpenic acids at all ^{5Reference 5Trauner G et al. · 2008Modulation of GABAA receptors by valerian extracts is related to the content of valerenic acidView study →}, where aqueous preparations largely do not — though it is worth noting that the largest systematic review of valerian concluded the whole root/rhizome gave the more reliable clinical signal, and that quality-control and standardisation methods need revising ^{15Reference 15Shinjyo N et al. · 2020Meta-analysisValerian root in treating sleep problems and associated disorders — a systematic review and meta-analysisView study →}. Those two positions are not fully reconciled, and that is not pretended otherwise.

What It's Used For

Acetoxyvalerenic acid has no therapeutic application. Its research record consists of one negative pharmacological finding (it does not modulate GABA-A), one interference finding (it blocks valerenic acid’s effect), and a substantial analytical literature in which it functions as a quality-control marker.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. Note that here a high score is not a benefit: the best-evidenced row is a quality-control role, and the second is an interference effect.

01Quality-control and standardisation markerPromising62%Pharmacopoeial assay analyte; validated HPLC-DAD and ATR-FTIR methods; multiple survey datasets ^{6,7,8,16,19Reference 6Raj K et al. · 2023Chemical diversity of wild-growing and cultivated common valerian (Valeriana officinalis L. s.l.) originating from PolandView study →Reference 7Nikzad-Langerodi R et al. · 2018Quality control of Valerianae Radix by attenuated total reflection Fourier transform infrared (ATR-FTIR) spectroscopyView study →Reference 8Navarrete A et al. · 2006Chemical fingerprinting of Valeriana species: simultaneous determination of valerenic acids, flavonoids, and phenylpropanoids using liquid chromatography with ultraviolet detectionView study →Reference 16Shohet D et al. · 2001Valepotriates and valerenic acids in commercial preparations of valerian available in AustraliaView study →Reference 19Lefebvre T et al. · 2004In vitroIn vitro activity of commercial valerian root extracts against human cytochrome P450 3A4View study →}

02Antagonism of the valerenic-acid anxiolytic effectShaky38%Two in-vivo mouse EPM studies, one research group, industry-funded, no independent replication ^{1,2Reference 1Becker A et al. · 2014The anxiolytic effects of a Valerian extract is based on valerenic acidView study →Reference 2Felgentreff F et al. · 2012Valerian extract characterized by high valerenic acid and low acetoxy valerenic acid contents demonstrates anxiolytic activityView study →}

03GABA-A activity of its ownShaky8%Negative result: no potentiation in oocyte electrophysiology; inhibition only at ≥100 µM ^{3,5Reference 3Khom S et al. · 2007Valerenic acid potentiates and inhibits GABA(A) receptors: molecular mechanism and subunit specificityView study →Reference 5Trauner G et al. · 2008Modulation of GABAA receptors by valerian extracts is related to the content of valerenic acidView study →}

Mechanisms

The load-bearing row is the first one — and it is the least firmly established. Everything practical about this molecule follows from the assumption that it sits in valerenic acid’s seat without doing valerenic acid’s job.

Pharmacokinetics

There is no dedicated pharmacokinetic study of acetoxyvalerenic acid in animals or humans, and what is known is assembled from adjacent work. It is poorly brain-penetrant: across an ECV304 blood–brain-barrier model all three valerenic acids permeated far more slowly than diazepam, with acetoxyvalerenic acid at 3.54 ± 0.58 µm/min (a factor of 0.09 relative to diazepam) and an exponential dependence on barrier tightness, implying paracellular or transporter-mediated rather than transcellular passage ^{9Reference 9Neuhaus W et al. · 2008In vitroTransport of a GABAA receptor modulator and its derivatives from Valeriana officinalis L. s. l. across an in vitro cell culture model of the blood-brain barrierView study →}. It is also metabolically labile in a specific way — incubation of valerian extract with fresh rat hepatocytes cut acetoxyvalerenic acid 9-fold with a corresponding 9-fold rise in hydroxyvalerenic acid, straightforward O-deacetylation ^{10Reference 10Simmen U et al. · 2005Preserved pharmacological activity of hepatocytes-treated extracts of valerian and StView study →} — and the same conversion appears as a storage-degradation route in dried root ^{18Reference 18Goppel M · 2004Stability control of valerian ground material and extracts: a new HPLC-method for the routine quantification of valerenic acids and lignansView study →}. Both facts cut against the antagonism mattering as much in a swallowed capsule as in a gavage experiment.

For scale, the better-characterised sibling: valerenic acid has an oral bioavailability of about 33.7% in rats, with a two-compartment disposition and a 2.7–5 h oral half-life ^{20Reference 20Sampath C et al. · 2012AnimalPharmacokinetics of valerenic acid in rats after intravenous and oral administrationsView study →}. In older women given valerian nightly, valerenic acid pharmacokinetics showed considerable inter- and intra-subject variability despite very low capsule-to-capsule variation in hydroxyvalerenic, acetoxyvalerenic and valerenic acid content (2.2%, 1.4% and 1.4% respectively) — variability the authors flagged as a contributor to valerian’s inconsistent effects ^{14Reference 14Anderson GD et al. · 2010Pharmacokinetics of valerenic acid after single and multiple doses of valerian in older womenView study →}. That is a second, independent source of inconsistency sitting alongside the ratio problem.

Clinical Trials

None. There are no clinical trials of acetoxyvalerenic acid, and there will not sensibly be any — it is not a candidate therapeutic. The clinically relevant untested question is different and quite specific: no human trial has compared a high-valerenic / low-acetoxyvalerenic extract against a conventional one at matched total sesquiterpenic-acid dose. That trial would directly test whether the mouse finding explains the human record. The nearest existing human data are the meta-analyses of valerian for sleep and anxiety, which attribute inconsistency to extract quality and call for revised standardisation — without isolating the ratio as the variable ^{15Reference 15Shinjyo N et al. · 2020Meta-analysisValerian root in treating sleep problems and associated disorders — a systematic review and meta-analysisView study →}.

Last checked: July 2026.

Isolate vs. Plant Studies

This molecule reverses the usual framing. Ordinarily the caution is that an isolate’s activity cannot be read onto the whole plant. Here the isolate was used as a deliberate spike into a whole-plant extract, and its effect was to subtract from the extract’s activity ^{1Reference 1Becker A et al. · 2014The anxiolytic effects of a Valerian extract is based on valerenic acidView study →} — a rare experimental design in phytotherapy, and the reason the finding is worth taking seriously despite its narrowness.

The distinctions that matter when reading the literature:

• The pure compound was never dosed alone for behaviour. Acetoxyvalerenic acid on its own has not been run through the elevated plus maze; it was only ever added to an active extract ^{1Reference 1Becker A et al. · 2014The anxiolytic effects of a Valerian extract is based on valerenic acidView study →}. So “acetoxyvalerenic acid is anxiogenic” is not a supported statement — the 1:1 anxiogenic result is a property of that mixture.
• The electrophysiology is on recombinant receptors in oocytes, not on the plant ^{3,5Reference 3Khom S et al. · 2007Valerenic acid potentiates and inhibits GABA(A) receptors: molecular mechanism and subunit specificityView study →Reference 5Trauner G et al. · 2008Modulation of GABAA receptors by valerian extracts is related to the content of valerenic acidView study →}.
• Whole-extract human evidence exists for valerian and none for this molecule, and the two should never be merged: valerian’s clinical record is a record of preparations, and this compound is one of the reasons those preparations are not interchangeable ^{15Reference 15Shinjyo N et al. · 2020Meta-analysisValerian root in treating sleep problems and associated disorders — a systematic review and meta-analysisView study →}.
• Species discipline applies. The valerenic acids are essentially a V. officinalis marker set ^{8Reference 8Navarrete A et al. · 2006Chemical fingerprinting of Valeriana species: simultaneous determination of valerenic acids, flavonoids, and phenylpropanoids using liquid chromatography with ultraviolet detectionView study →}; findings here say nothing about the valepotriate-rich Indian (V. jatamansi) or Mexican (V. edulis) valerians, whose active chemistry runs through valtrate instead.

Prevalence in Nature

Acetoxyvalerenic acid is a narrow, taxonomically informative molecule. It is found in Valeriana officinalis s.l. as one of three co-occurring valerenic acids, in trace amounts in V. sitchensis, and was not detected in the other Valeriana species assayed in a multi-species chemical fingerprinting study ^{8Reference 8Navarrete A et al. · 2006Chemical fingerprinting of Valeriana species: simultaneous determination of valerenic acids, flavonoids, and phenylpropanoids using liquid chromatography with ultraviolet detectionView study →} — which is precisely why the group is used for species authentication.

Its content is anything but fixed. In the 2023 Polish survey, cultivated tetraploid ‘Lubelski’ forms carried 0.146–0.188% dry weight (mean 0.171%), against 0.002% in wild diploid populations, with coefficients of variation of 19–59% between forms ^{6Reference 6Raj K et al. · 2023Chemical diversity of wild-growing and cultivated common valerian (Valeriana officinalis L. s.l.) originating from PolandView study →}. Ploidy is a real driver — octoploid cytotypes are the most productive for sesquiterpenic acids ^{7Reference 7Nikzad-Langerodi R et al. · 2018Quality control of Valerianae Radix by attenuated total reflection Fourier transform infrared (ATR-FTIR) spectroscopyView study →} — as are harvest month (the acids peak February–March) ^{12Reference 12Bos R et al. · 1998Seasonal variation of the essential oil, valerenic acid and derivatives, and valepotriates in Valeriana officinalis roots and rhizomes, and the selection of plants suitable for phytomedicinesView study →}, plant age, and soil biology: mycorrhizal inoculation raised root sesquiterpenic-acid concentrations, though not yield per plant, and one genotype behaved as a distinct hydroxyvalerenic acid chemotype ^{13Reference 13Nell M et al. · 2010Root colonization by symbiotic arbuscular mycorrhizal fungi increases sesquiterpenic acid concentrations in Valeriana officinalis LView study →}. In the finished-product world the spread widens further, from <0.01 to 6.32 mg/g of total valerenic acids across 31 commercial Australian preparations ^{16Reference 16Shohet D et al. · 2001Valepotriates and valerenic acids in commercial preparations of valerian available in AustraliaView study →}.

The molecule also sits in a small interconversion family with its two relatives: acetoxyvalerenic acid deacetylates to hydroxyvalerenic acid both metabolically ^{10Reference 10Simmen U et al. · 2005Preserved pharmacological activity of hepatocytes-treated extracts of valerian and StView study →} and on storage ^{18Reference 18Goppel M · 2004Stability control of valerian ground material and extracts: a new HPLC-method for the routine quantification of valerenic acids and lignansView study →}, so a given root’s ratio is not stable over shelf life.

Discovery & Synthesis

Acetoxyvalerenic acid does not have a clean discovery story, and it will not be invent one. It entered the literature not as a discovery in its own right but as one member of the “valerenic acids” — the sesquiterpenic acid group characterised in Valeriana officinalis alongside valerenic acid and hydroxyvalerenic acid — and by the 1990s it was being routinely quantified in seasonal-variation and cytotoxicity studies as a matter of course ^{11,12Reference 11Bos R et al. · 1998Cytotoxic potential of valerian constituents and valerian tincturesView study →Reference 12Bos R et al. · 1998Seasonal variation of the essential oil, valerenic acid and derivatives, and valepotriates in Valeriana officinalis roots and rhizomes, and the selection of plants suitable for phytomedicinesView study →}. No first-isolation primary could be verified; the gap is logged rather than papered over.

Structurally it is valerenic acid’s scaffold bearing an acetate ester (C17H24O4, MW 292.4), and biosynthetically it is best understood as the acetylated form of hydroxyvalerenic acid — a relationship that runs in reverse readily, since simple O-deacetylation converts it back to hydroxyvalerenic acid in hepatocytes and during storage ^{10,18Reference 10Simmen U et al. · 2005Preserved pharmacological activity of hepatocytes-treated extracts of valerian and StView study →Reference 18Goppel M · 2004Stability control of valerian ground material and extracts: a new HPLC-method for the routine quantification of valerenic acids and lignansView study →}.

It is not manufactured. Its only commercial existence is as an analytical reference standard for HPLC calibration ^{6Reference 6Raj K et al. · 2023Chemical diversity of wild-growing and cultivated common valerian (Valeriana officinalis L. s.l.) originating from PolandView study →}, and the only “synthesis” of practical interest around this scaffold has gone the other way — toward valerenic acid derivatives designed to be better GABA-A modulators, not worse ones ^{4Reference 4Benke D et al. · 2009AnimalGABA-A receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extractsView study →}.

Patents: not yet researched.

Toxicity & Safety

Acetoxyvalerenic acid carries a low flag on conventional toxicity grounds. In a direct comparison of valerian constituents against two human cancer cell lines, the valerenic acids — valerenic, acetoxyvalerenic, hydroxyvalerenic and methyl valerenate — showed IC50 values of 100–200 µM, placing them among the least cytotoxic constituents tested and roughly 20–200 times weaker than the diene-type valepotriates such as valtrate (IC50 1–6 µM) ^{11Reference 11Bos R et al. · 1998Cytotoxic potential of valerian constituents and valerian tincturesView study →}. No genotoxicity, organ-toxicity or reproductive-toxicity signal is attached to this molecule specifically, and it has never been dosed to humans as an isolate.

The relevant issue with this compound is not that it does harm. It is that it may quietly remove benefit from a product the user believes is working.

Safety at a Glance

✅ Low / no toxicity

• Low intrinsic toxicity. Among the least cytotoxic valerian constituents in direct comparison (IC50 100–200 µM), far below the valepotriates.
• No isolate exposure in practice. Nobody takes acetoxyvalerenic acid deliberately; exposure is only as a constituent of ordinary valerian preparations.
• It can cancel the effect you are paying for. At ratios typical of commercial valerian, it abolished a valerian extract’s anxiolytic effect in mice at matched total acid dose ^{1,2Reference 1Becker A et al. · 2014The anxiolytic effects of a Valerian extract is based on valerenic acidView study →Reference 2Felgentreff F et al. · 2012Valerian extract characterized by high valerenic acid and low acetoxy valerenic acid contents demonstrates anxiolytic activityView study →}.
• Label figures may not mean what they say. Pharmacopoeial standardisation sums this compound with valerenic acid and reports the total as valerenic acid, so a compliant product can be dominated by the inactive form.
• The findings are thin. One research group, two mouse studies, industry-funded, no independent replication and no human data — a serious hypothesis, not an established fact.

Full Safety & Interactions Detail

Cytotoxicity. The 1998 Groningen comparison remains the primary datum: valerenic acid, acetoxyvalerenic acid, hydroxyvalerenic acid and methyl valerenate all gave IC50 values between 100 and 200 µM against GLC4 (small-cell lung) and COLO 320 (colorectal) cells in the MTT assay, while diene valepotriates ran at 1–6 µM and their baldrinal breakdown products at 10–30x weaker than the parents ^{11Reference 11Bos R et al. · 1998Cytotoxic potential of valerian constituents and valerian tincturesView study →}. Valerian tincture cytotoxicity tracked valepotriate content, not valerenic acid content ^{11Reference 11Bos R et al. · 1998Cytotoxic potential of valerian constituents and valerian tincturesView study →}. Nothing in this molecule’s profile suggests it contributes meaningfully to valerian’s (already modest) toxicity picture.

Interactions — an extract-level, not molecule-level, issue. Commercial valerian root extracts inhibited CYP3A4-mediated metabolism and P-glycoprotein transport in vitro, across products whose hydroxyvalerenic, acetoxyvalerenic and valerenic acid contents varied widely and often disagreed with their labels ^{19Reference 19Lefebvre T et al. · 2004In vitroIn vitro activity of commercial valerian root extracts against human cytochrome P450 3A4View study →}. That signal belongs to the extract, was not attributed to any single constituent, and has not been shown to translate in vivo — but it is the reason valerian carries a general “check interactions” caution rather than anything specific to this compound. Additive sedation with CNS depressants likewise belongs to the valerian herb page, where intake is actually decided.

The distinctive risk here is anti-efficacy. Practically, a valerian product high in acetoxyvalerenic acid relative to valerenic acid may underperform — and, on the strength of one mouse experiment at a 1:1 ratio, may conceivably do the opposite of what is wanted ^{1Reference 1Becker A et al. · 2014The anxiolytic effects of a Valerian extract is based on valerenic acidView study →}. That single anxiogenic data point should not be over-read: it was a mixture effect at one ratio in one model, was non-monotonic, and has not been replicated. It is a reason to prefer separately-declared valerenic acid, not a reason to treat valerian as hazardous.

Reproductive note (prose only). No reproductive-toxicity dataset exists for isolated acetoxyvalerenic acid, and none would be expected for a non-therapeutic constituent. Pregnancy and lactation decisions belong to the valerian herb or product page, where the actual exposure is chosen, not to this molecule.

Dosage

There is no dose of acetoxyvalerenic acid, and the sensible goal is less of it rather than more. It has no therapeutic use, no established human exposure as an isolate, and no reason to be taken deliberately. What follows are the figures that appear in the literature, for orientation only — they are research and analytical values, not a recommendation.

The one practically actionable line: look for a valerian product that reports valerenic acid separately from acetoxyvalerenic acid, and read a combined “valerenic acids” figure as a ceiling on the active fraction rather than a measure of it ^{1Reference 1Becker A et al. · 2014The anxiolytic effects of a Valerian extract is based on valerenic acidView study →}. Actual valerian dosing — root, tincture or extract, for insomnia, anxiety or otherwise — belongs on the valerian page.

References

1. Becker A, Felgentreff F, Schröder H, Meier B, Brattström A (2014). The anxiolytic effects of a Valerian extract is based on valerenic acid. BMC Complementary and Alternative Medicine. https://pubmed.ncbi.nlm.nih.gov/25066015/
2. Felgentreff F, Becker A, Meier B, Brattström A (2012). Valerian extract characterized by high valerenic acid and low acetoxy valerenic acid contents demonstrates anxiolytic activity. Phytomedicine. https://pubmed.ncbi.nlm.nih.gov/22944521/
3. Khom S, Baburin I, Timin E, Hohaus A, Trauner G, Kopp B, Hering S (2007). Valerenic acid potentiates and inhibits GABA(A) receptors: molecular mechanism and subunit specificity. Neuropharmacology. https://pubmed.ncbi.nlm.nih.gov/17585957/
4. Benke D, Barberis A, Kopp S, Altmann KH, Schubiger M, Vogt KE, Rudolph U, Möhler H (2009). GABA-A receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extracts. Neuropharmacology. https://pubmed.ncbi.nlm.nih.gov/18602406/
5. Trauner G, Khom S, Baburin I, Benedek B, Hering S, Kopp B (2008). Modulation of GABAA receptors by valerian extracts is related to the content of valerenic acid. Planta Medica. https://pubmed.ncbi.nlm.nih.gov/18095218/
6. Raj K, Węglarz Z, Przybył JL, Kosakowska O, Pawełczak A, Gontar Ł, Puchta-Jasińska M, Bączek K (2023). Chemical diversity of wild-growing and cultivated common valerian (Valeriana officinalis L. s.l.) originating from Poland. Molecules. https://pubmed.ncbi.nlm.nih.gov/38202695/
7. Nikzad-Langerodi R, Arth K, Klatte-Asselmeyer V, Bressler S, Saukel J, Reznicek G, Dobeš C (2018). Quality control of Valerianae Radix by attenuated total reflection Fourier transform infrared (ATR-FTIR) spectroscopy. Planta Medica. https://pubmed.ncbi.nlm.nih.gov/29121679/
8. Navarrete A, Avula B, Choi YW, Khan IA (2006). Chemical fingerprinting of Valeriana species: simultaneous determination of valerenic acids, flavonoids, and phenylpropanoids using liquid chromatography with ultraviolet detection. Journal of AOAC International. https://pubmed.ncbi.nlm.nih.gov/16512222/
9. Neuhaus W, Trauner G, Gruber D, Oelzant S, Klepal W, Kopp B, Noe CR (2008). Transport of a GABAA receptor modulator and its derivatives from Valeriana officinalis L. s. l. across an in vitro cell culture model of the blood-brain barrier. Planta Medica. https://pubmed.ncbi.nlm.nih.gov/18704879/
10. Simmen U, Saladin C, Kaufmann P, Poddar M, Wallimann C, Schaffner W (2005). Preserved pharmacological activity of hepatocytes-treated extracts of valerian and St. John’s wort. Planta Medica. https://pubmed.ncbi.nlm.nih.gov/16041642/
11. Bos R, Hendriks H, Scheffer JJ, Woerdenbag HJ (1998). Cytotoxic potential of valerian constituents and valerian tinctures. Phytomedicine. https://pubmed.ncbi.nlm.nih.gov/23195845/
12. Bos R, Woerdenbag HJ, van Putten FM, Hendriks H, Scheffer JJ (1998). Seasonal variation of the essential oil, valerenic acid and derivatives, and valepotriates in Valeriana officinalis roots and rhizomes, and the selection of plants suitable for phytomedicines. Planta Medica. https://pubmed.ncbi.nlm.nih.gov/9556440/
13. Nell M, Wawrosch C, Steinkellner S, Vierheilig H, Kopp B, Lössl A, Franz C, Novak J, Zitterl-Eglseer K (2010). Root colonization by symbiotic arbuscular mycorrhizal fungi increases sesquiterpenic acid concentrations in Valeriana officinalis L. Planta Medica. https://pubmed.ncbi.nlm.nih.gov/19809971/
14. Anderson GD, Elmer GW, Taibi DM, Vitiello MV, Kantor E, Kalhorn TF, Howald WN, Barsness S, Landis CA (2010). Pharmacokinetics of valerenic acid after single and multiple doses of valerian in older women. Phytotherapy Research. https://pubmed.ncbi.nlm.nih.gov/20878691/
15. Shinjyo N, Waddell G, Green J (2020). Valerian root in treating sleep problems and associated disorders — a systematic review and meta-analysis. Journal of Evidence-Based Integrative Medicine. https://pubmed.ncbi.nlm.nih.gov/33086877/
16. Shohet D, Wills RB, Stuart DL (2001). Valepotriates and valerenic acids in commercial preparations of valerian available in Australia. Pharmazie. https://pubmed.ncbi.nlm.nih.gov/11817170/
17. Boyadzhiev L, Kancheva D, Gourdon C, Metcheva D (2004). Extraction of valerenic acids from valerian (Valeriana officinalis L.) rhizomes. Pharmazie. https://pubmed.ncbi.nlm.nih.gov/15497760/
18. Goppel M, Franz G (2004). Stability control of valerian ground material and extracts: a new HPLC-method for the routine quantification of valerenic acids and lignans. Pharmazie. https://pubmed.ncbi.nlm.nih.gov/15248459/
19. Lefebvre T, Foster BC, Drouin CE, Krantis A, Livesey JF, Jordan SA (2004). In vitro activity of commercial valerian root extracts against human cytochrome P450 3A4. Journal of Pharmacy & Pharmaceutical Sciences. https://pubmed.ncbi.nlm.nih.gov/15367385/
20. Sampath C, Haug K, Thanei S, Hamburger M, Derendorf H, Frye R, Butterweck V (2012). Pharmacokinetics of valerenic acid in rats after intravenous and oral administrations. Planta Medica. https://pubmed.ncbi.nlm.nih.gov/22411722/

View all 20 references▾